Welcome to our dedicated page for FOXO TECHNOLOGIES SEC filings (Ticker: FOXOD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on FOXO TECHNOLOGIES's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into FOXO TECHNOLOGIES's regulatory disclosures and financial reporting.
FOXO Technologies Inc., through its subsidiary Vector BioSource, Inc., has entered into a definitive agreement to acquire four U.S.-based blood collection centers from Grifols Bio Supplies, Inc. in an asset purchase including an upfront cash payment and a potential earnout tied to EBITDA targets in 2026, 2027 or 2028.
The acquisition is intended to create a proprietary source of bio-products and support new FDA licensure that is expected to expand Vector’s accessible market. Based on historical information and current estimates, FOXO states the acquisition should add over $10 million in net revenues during the twelve months following closing, although actual results may differ materially. Closing is anticipated in the third or fourth quarter of 2026, subject to customary closing conditions, including required FDA licensure and other regulatory authorizations.
FOXO Technologies Inc., through its subsidiary Vector BioSource, Inc., agreed to acquire certain assets and assume certain liabilities tied to four U.S.-based blood collection centers from Grifols Bio Supplies, Inc. The asset purchase agreement provides for $3,500,000 in cash at closing plus a contingent earn-out of up to $1,000,000 in cash.
The full earn-out becomes payable if the acquired business generates EBITDA of $1,500,000 or more in any single calendar year during 2026–2028. Closing is subject to customary conditions and to Vector obtaining its own FDA license, CLIA certifications in relevant states, and a Miami waste-management permit. Either party may terminate if closing has not occurred within nine months after July 22, 2026, and the company currently anticipates closing in the third or fourth quarter of 2026.